Table A2.
The association between immunogenicity and individual’s health state, antipyretics, and reactogenicity index.
| Anti-S1 Antibody | sVNT | T-Spot | ||||||
|---|---|---|---|---|---|---|---|---|
| Variables (N) | Mean (SD) | p | Mean (SD) | p | Mean (SD) | p | ||
| Sex | Male (21) | 5.2 (±1.9) | 0.73 | 73.7 (±20.9) | 0.73 | 12.9 (±7.8) | 0.08 | |
| Female (58) | 5.4 (±1.5) | 75.4 (±18.7) | 9.3 (±7.4) | |||||
| Age | <40 (55) | 5.4 (±1.6) | 0.47 | 76.6 (±17.7) | 0.31 | 9.8 (±7.6) | 0.58 | |
| ≥40 (24) | 5.1 (±1.8) | 71.2 (±22.2) | 10.9 (±7.7) | |||||
| Smoking | No (70) | 5.3 (±1.7) | 0.26 | 74.0 (±19.5) | 0.23 | 10.1 (±7.9) | 0.83 | |
| Yes (9) | 5.9 (±1.3) | 82.2 (±16.1) | 10.7 (±4.8) | |||||
| Alcohol consumption | Mild to moderate (45) | 5.3 (±1.5) | 0.98 | 75.5 (±18.6) | 0.78 | 8.9 (±5.9) | 0.13 | |
| Heavy or binge (34) | 5.3 (±1.7) | 74.2 (±20.2) | 11.9 (±9.3) | |||||
| BMI | <25 (57) | 5.2 (±1.5) | 0.44 | 74.2 (±18.3) | 0.51 | 10.1 (±7.9) | 0.08 | |
| 25–30 (18) | 5.7 (±0.4) | 78.7 (±19.8) | 11.8 (±6.7) | |||||
| >30 (4) | 6.1 (±0.8) | 68.8 (±31.4) | 4.0 (±5.0) | |||||
| Pulmonary tuberculosis | No (75) | 5.3 (±1.6) | 0.43 | 74.4 (±19.3) | 0.27 | 10.2 (±7.7) | 0.92 | |
| Yes(4) | 6.0 (±0.8) | 85.4 (±15.7) | 7.8 (±6.0) | |||||
| HTN | No (76) | 5.3 (±1.6) | 0.90 | 75.2 (±19.0) | 0.50 | 10.3 (±7.7) | 0.47 | |
| Yes (3) | 5.5 (±2.8) | 67.7 (±26.4) | 7.0 (±3.5) | |||||
| Dyslipidemia | No (76) | 5.3 (±1.6) | 0.94 | 74.7 (±19.0) | 0.62 | 10.1 (±7.7) | 0.78 | |
| Yes (3) | 5.4 (±1.8) | 80.4 (±28.5) | 11.3 (±5.8) | |||||
| DM | No (78) | 5.4 (±1.6) | 0.24 | 75.3 (±19.1) | 0.15 | 10.2 (±7.6) | 0.50 | |
| Yes (1) | 3.5 (±NA) | 47.5 (±NA) | 5.0 (±NA) | |||||
| Abnormal LFT | No (71) | 5.4 (±1.7) | 0.90 | 75.1 (±18.7) | 0.84 | 10.3 (±7.8) | 0.67 | |
| Yes (8) | 5.3 (±1.4) | 73.7 (±24.5) | 9.1 (±5.9) | |||||
| Abnormal RFT | No (72) | 5.3 (±1.6) | 0.25 | 74.7 (±19.5) | 0.75 | 9.6 (±7.0) | 0.19 | |
| Yes (7) | 6.0 (±1.4) | 77.1 (±16.8) | 15.7 (±11.0) | |||||
| Physical activity | Lack (42) | 5.2 (±1.6) | 0.52 | 73.1 (±21.2) | 0.36 | 10.6 (±7.4) | 0.60 | |
| Adequate (37) | 5.5 (±1.6) | 77.0 (±16.7) | 9.6 (±7.9) | |||||
| Muscle exercise | Lack (52) | 5.3 (±1.4) | 0.80 | 74.0 (±18.7) | 0.55 | 9.1 (±7.0) | 0.09 | |
| Adequate (27) | 5.4 (±1.9) | 76.8 (±20.4) | 12.4 (±8.6) | |||||
| 1st dose | Antipyretics | No (8) | 5.4 (±1.5) | 0.68 | 76.2 (±17.9) | 0.14 | 10.1 (±7.7) | 0.97 |
| Yes (69) | 5.0 (±2.5) | 66.5 (±26.1) | 10.3 (±7.3) | |||||
| Antipyretics intake | Prophylactic (30) | 5.4 (±1.5) | 0.58 | 75.1 (±17.5) | 0.62 | 10.5 (±7.4) | 0.76 | |
| After symptom onset (39) | 5.4 (±1.5) | 77.4 (±18.4) | 9.9 (±8.1) | |||||
| 2nd dose | Antipyretics | No (28) | 5.4 (±1.5) | 0.83 | 76.1 (±17.6) | 0.46 | 10.6 (±8.4) | 0.51 |
| Yes (51) | 5.3 (±1.8) | 72.8 (±21.9) | 9.3 (±5.7) | |||||
| Antipyretics intake | Prophylactic (24) | 5.5 (±1.8) | 0.51 | 76.3 (±17.2) | 0.85 | 11.9 (±8.9) | 0.33 | |
| After symptom onset (27) | 5.2 (±1.3) | 75.4 (±18.3) | 9.5 (±8.3) | |||||
| SRI | <13 (37) | 5.3 (±1.8) | 0.81 | 72.9 (±21.0) | 0.38 | 10.8 (±7.8) | 0.49 | |
| ≥13 (42) | 5.4 (±1.5) | 76.8 (±17.5) | 9.6 (±7.5) | |||||
| SRID | <29 (40) | 5.4 (±1.8) | 0.75 | 74.6 (±20.8) | 0.88 | 11.3 (±7.7) | 0.21 | |
| ≥29 (39) | 5.3 (±1.5) | 75.3 (±17.6) | 9.1 (±7.5) | |||||
BMI; body mass index, HTN; hypertension, DM; diabetes mellitus, LFT; liver function test, RFT; renal function test. Data are presented as mean ± standard deviation for continuous variables. S/Co; signal to cut-off, sVNT; surrogate virus neutralization test.